Onxeo's Combined General Meeting on June 10, 2021 in Camera: Availability of Preparatory Documents & Live Webcast Login Infor...
21 Maggio 2021 - 5:45PM
Business Wire
Regulatory News:
Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO -
FR0010095596), (“Onxeo”, “the Company” or “the Group”), a
clinical-stage biotechnology company specializing in the
development of innovative drugs targeting tumor DNA Damage response
(DDR) in oncology, in particular against rare or resistant cancers,
announces today the availability of the preparatory documents for
its Combined General Meeting of June 10, 2021 and specifies the
live webcast login information.
In the context of the Covid-19 pandemic, the Combined General
Meeting on June 10, 2021 at 03:00 p.m., will be held in camera,
without the presence of shareholders or other persons usually
eligible to attend.
The General Meeting will be webcasted live (in French) via a web
conferencing system and shareholders of Onxeo are invited to login
through the following link:
https://us02web.zoom.us/webinar/register/WN_GkVbNWV8RhutMoH7cekSyw
- This link allows shareholders to pre-register for the General
Meeting by indicating your name, first name and
e-mail. They will then receive a confirmation of their
registration with the possibility to add the event to their
agenda.
- On June 10, 2021, the shareholders will be able to log on to
this same link. The Meeting will start at 03:00 pm sharp and they
will be able to follow the presentation commented by the management
of Onxeo and the course of the Meeting directly on their
computer.
- At any time during the presentation, they will be able to send
their questions via the web platform. Questions will be answered
during the Q&A session*.
In accordance with current regulations and the recent
recommendations of the French stock-market authority (AMF), Onxeo
shareholders are requested to cast their votes exclusively
through mail or online voting prior to the General Meeting:
- online voting is available and must be
used as a priority: the secure voting platforms
VOTACCESS in France and Computershare in Denmark will
be active on May 21, 2021 at 9 a.m.;
- alternatively, shareholders can also vote
by postal ballot, in accordance with the terms and conditions
indicated in the prior notice published in the BALO on May 5,
2021.
All documents relating to this General Meeting are available on
the company's website, in the General Meetings section.
The Meeting will be chaired by Mrs Danièle Guyot-Caparros as
Chairman of the Board of Directors. Mr. Nicolas Fellmann, Chief
Financial Officer of the Company, will act as Secretary of the
Bureau. In accordance with the terms of Article 8 of Decree dated
December 18, 2020, Financière de la Montagne, represented by Mr.
Nicolas Trebouta, and Invus Public Equities LP, represented by Mr.
Julien Miara, have been appointed scrutineers and have agreed to
perform these duties.
If you have any questions about voting procedures, please
contact the Investor Relations team by e-mail at
ag2021@onxeo.com.
* Please note that, given the impossibility of verifying the
shareholder status of participants in the video transmission, the
Q&A session is informal and has no legal value within the
meaning of Article L 225-108 of the French Commercial Code. The
procedures for written questions from shareholders within the
meaning of the regulations are detailed in the notice of meeting
published in the BALO and the JAL on May 21, 2021 and available on
the Company's website.
About Onxeo
Onxeo (Euronext Growth Paris: ALONX, Nasdaq First North
Copenhagen: ONXEO) is a clinical-stage biotechnology company
developing innovative oncology drugs targeting tumor DNA-binding
functions through unique mechanisms of action in the sought-after
field of DNA Damage Response (DDR). The Company is focused on
bringing early-stage first-in-class or disruptive compounds from
translational research to clinical proof-of-concept, a
value-creating inflection point appealing to potential partners.
platON™ is Onxeo’s proprietary chemistry platform of
oligonucleotides acting as decoy agonists, which generates new
innovative compounds and broaden the Company’s product pipeline.
AsiDNA™, the first compound from platON™, is a
first-in-class, highly differentiated DNA Damage Response (DDR)
inhibitor based on a decoy and agonist mechanism acting upstream of
multiple DDR pathways. Translational research has highlighted the
distinctive properties of AsiDNA™, notably its ability to abrogate
tumor resistance to PARP inhibitors regardless of the genetic
mutation status. AsiDNA™ has also shown a strong synergy with other
tumor DNA-damaging agents such as chemotherapy and PARP inhibitors.
The DRIIV-1 (DNA Repair Inhibitor-administered IntraVenously) phase
I study has evaluated AsiDNA™ by systemic administration (IV) in
advanced solid tumors and confirmed the active doses as well as a
favorable human safety profile. The ongoing DRIIV-1b extension
study is evaluating the safety and efficacy of AsiDNA™ at a dose of
600 mg in combination with the reference chemotherapy, carboplatin
-/+ paclitaxel, in advanced metastatic tumors. Preliminary results
from both cohorts showed good tolerability, stabilization of the
disease and an increase in treatment duration compared to previous
treatments. The ongoing REVOCAN phase 1b/2 study evaluates the
effect of AsiDNA™ on the acquired resistance to PARP inhibitor
niraparib in relapsed ovarian cancer (sponsored by Gustave Roussy).
A phase 1b/2 study, AsiDNA™ Children, will be initiated in 2021 to
evaluate the association of AsiDNA™ with radiotherapy in children
with relapsed high-grade glioma (sponsored by Institut Curie).
OX401 is a new drug candidate from platON™, optimized to be
a next-generation PARP inhibitor acting on both the DNA Damage
Response and the activation of immune response, without inducing
resistance. OX401 is undergoing preclinical proof-of-concept
studies, alone and in combination with immunotherapies.
For further information, please visit www.onxeo.com.
Forward looking statements This communication expressly
or implicitly contains certain forward-looking statements
concerning Onxeo and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors, which
could cause the actual results, financial condition, performance or
achievements of Onxeo to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Onxeo is providing this communication
as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise. For a discussion of risks
and uncertainties which could cause actual results, financial
condition, performance or achievements of Onxeo to differ from
those contained in the forward-looking statements, please refer to
the risk factors described in the most recent Company’s
registration document or in any other periodic financial report and
in any other press release, which are available free of charge on
the websites of the Company Group (www.onxeo.com) and/or the AMF
(www.amf-france.org).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210521005304/en/
Onxeo Valerie Leroy, Investor Relations investors@onxeo.com +33 1 45 58 76 00
Media Relations Nicolas Merigeau NewCap onxeo@newcap.eu +33 1 44 71 94 98
Investor Relations / Strategic Communication Dušan
Orešanský / Emmanuel Huynh NewCap onxeo@newcap.eu +33 1 44 71 94 92